Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 357-362

  Sanseau, Ana ^a   Sampaolesi, Juan ^b   Suzuki, Emilio Rintaro ^c   Lopes, Joao Franca ^d   Borel, Hector ^e  

^a Instituto de la Vision Ciudad Autonoma de Buenos Aires   (Argentina)

^b Ciudad de Buenos Aires   (Argentina)

^c Oftalmoclinica Curitiba   (Brazil)

^d Hospital El Salvador   (Chile)

^e NONE   (Chile)

Author keywords

Brinzolamide; Dorzolamide; Fixed combination; Ocular discomfort; Patient preference; Timolol

Indexed keywords

BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL;

ADULT; AGED; ARTICLE; BITTER TASTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY THROAT; EYE DISCOMFORT; FEMALE; HUMAN; INFLUENZA; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLIT LAMP; TREATMENT DURATION; VISUAL ACUITY;

EID: 84874812095     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s38575     Document Type: Article

References (21)

1. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121(1):48-56.
2. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440.
3. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-720; discussion 829-830.
4. Miglior S, Torri V, Zeyen T, Pfeiffer N, Vaz JC, Adamsons I; the EGPS Group. Intercurrent factors associated with the development of open-angle glaucoma in the European Glaucoma Prevention Study. Am J Ophthalmol. 2007;144(2):266-275.
5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hyperten-sion Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713; discussion 829-830.
6. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd ed. Savona, Italy: Dogma; 2008.
7. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol/0.5% fixed combination versus dorzolamide 2%/timolol/0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293-300.
8. Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011;27(10):1949-1958.
9. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15(2):132-135.
10. Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24(12): 1007-1016.
11. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003; 12(5):393-398.
12. Mundorf TK, Rauchman SH, Williams RD, Notivol R; the Brinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2(3):623-628.
13. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2008;24(6): 601-605.
14. Rossi GC, Pasinetti GM, Sandolo F, Bordin M, Bianchi PE. From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study. Expert Opin Pharmacother. 2011;12(16):2425-2431.
15. Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291-298.
16. AZARGA® Eye Drops Suspension [summary of product charac-teristics]. Hünenberg, Switzerland: Alcon Laboratories, Inc; 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info rmation/human/000960/WC500029827.pdf. Accessed. April 30, 2012.
17. COSOPT® Sterile Ophthalmic Solution [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2011.
18. Syed MF, Loucks EK. Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2011;5:1291-1296.
19. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204-1212.
20. Rossi GC, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21(4):410-414.
21. Doherty M, Fraser S, Phelan P. Brinzolamide-timolol suspension: acceptability and side effect profile. Clin Ophthalmol. 2011;5: 419-423.